Ara
Toplam kayıt 68, listelenen: 51-60
Comparison of response and survival of first-line crizotinib therapy according to EML-4 ALK fusion variants in advanced non-small cell lung cancer patients: A Turkish Oncology Group study
(Zerbinis Publications, 2021)
Purpose: In the literature there are conflicting data about the treatment efficacy of anaplastic lymphoma kinase (ALK) translocation positive non-small cell lung cancer (NSCLC) patients according to ALK fusion variants. ...
Real-life analysis of immunotherapy as the second or later lines treatment in patients with metastatic non-small cell lung cancer
(Ankara Society of Hematology and Oncology, 2021)
Background: Immunotherapy agents such as atezolizumab and nivolumab are appropriate option for non-small cell lung cancer (NSCLC) accounts in the absence of driver mutation, regardless of PDL-1 expression in second and ...
Markov Chain transition probability modeling of radon gas records and future projection possibility determination
(Elsevier Ltd, 2023)
Markov Chain models serve two purposes firstly, subdivide the main data based on the mean value and one and two standard deviation plus and minus values around the mean value. The second stage of modeling, after calculating ...
Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy
(NLM (Medline), 2023)
Atezolizumab is now the standard treatment for extensive-stage small cell lung cancer (ES-SCLC). Herein, we investigated the prognostic role of inflammatory markers in patients treated with atezolizumab plus chemotherapy ...
The optimal treatment approaches and prognostic factors in elderly patients with advanced stage biliary tract tumors
(Ankara Hematology Oncology Association, 2023)
Introduction: There is a lack of evidence of the outcomes in elderly patients advanced stage biliary tract cancer due to the patients aged over 65 years are less than 25% in many prospective trials. We designed a retrospective ...
Clinicopathological and survival characteristics of mismatch repair status and PD-1 expression in serous ovarian cancer
(College of Physicians and Surgeons Pakistan, 2023)
Objective: To evaluate the clinicopathological characteristics of mismatch repair (MMR) deficiency and its clinical outcomes by performing immunohistochemistry (IHC) for MMR genes in the serous ovarian cancer (SOC) tumour ...
Survival effect of palliative radiotherapy in patients with metastatic castration-resistant prostate cancer developing oligo-progression under antiandrogen treatment
(Istanbul University, 2023)
Objective: Androgen pathway inhibitors have a significant impact on the treatment of prostate cancer. The treatment approach is controversial in patients who develop oligo-pro-gression under anti-androgen therapy. This ...
The impact of hybrid capture-based comprehensive genomic profiling on treatment strategies in patients with solid tumors
(Turkiye Klinikleri, 2022)
Objective: The development of bioinformatics and comprehensive genomic profiling (CGP) has provided insights into the ap-plicability and functionality of the genomic alterations (GA). In this study, we evaluated the impact ...
The prognostic utility of the metastatic lymph node ratio and the number of regional lymph nodes removed from patients with small bowel adenocarcinomas
(MDPI, 2023)
Background and Objectives: Small bowel adenocarcinomas (SBAs) are rare tumors of the gastrointestinal system. Lymph node metastasis in patients with curatively resected SBAs is associated with poor prognosis. In this study, ...
Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study
(Springer, 2023)
Objectives To compare the survival of first- and second-generation tyrosine kinase inhibitors (TKIs) in patients with rare EGFR exon 18 and exon 20 mutation-positive non-small cell lung cancer (NSCLC). Materials and methods ...